Switzerland · Delayed Price · Currency is CHF Medartis Holding AG Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 31% year-over-year to CHF 160.8 million, with 17% organic growth and EBITDA margin rising to 18%. Upgraded guidance now targets 17%-19% organic sales growth for the year, driven by strong U.S. and EMEA performance and the successful KeriMedical TOUCH rollout.
-
Strong growth and innovation continue, with the TOUCH prosthesis driving rapid adoption and market expansion, especially in the U.S. and Europe. Financial guidance is reaffirmed, ESG and culture initiatives are advancing, and new production and education investments support scalability and long-term leadership.
Fiscal Year 2025
-
2025 saw double-digit organic growth, major acquisitions, and the successful U.S. launch of TOUCH, driving strong performance across all regions. Despite FX and tariff headwinds, margins improved and investments in production and innovation set the stage for 2026 growth.
-
Organic revenue grew 15.3% in H1, with strong EMEA and U.S. performance and successful integration of KeriMedical and NEOORTHO. Raised full-year growth guidance to 14%-16% and maintained high teens EBITDA margin despite tariffs and FX headwinds.
Fiscal Year 2024
-
Core revenue grew 11.7% to CHF 224.8 million with a 19% EBITDA margin, led by EMEA. 2025 guidance targets 13-15% organic growth and high teens EBITDA margin, with U.S. acceleration and NeoOrtho acquisition set to drive value segment expansion.
-
Achieved 13.1% underlying growth and improved gross margin to 80.3%, with strong U.S. and EMEA performance offset by LATAM and APAC challenges. Revised full-year CER growth guidance to 12%-15% and EBITDA margin to around 15%, while strengthening cash reserves and preparing for future acquisitions.